Federated Hermes Inc. Boosts Stock Position in Johnson & Johnson (NYSE:JNJ)

Federated Hermes Inc. boosted its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 48.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,108,370 shares of the company's stock after buying an additional 1,011,533 shares during the quarter. Johnson & Johnson accounts for approximately 1.0% of Federated Hermes Inc.'s portfolio, making the stock its 11th largest holding. Federated Hermes Inc. owned 0.13% of Johnson & Johnson worth $449,532,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Waterloo Capital L.P. increased its position in shares of Johnson & Johnson by 11.7% in the fourth quarter. Waterloo Capital L.P. now owns 16,098 shares of the company's stock valued at $2,328,000 after buying an additional 1,681 shares in the last quarter. Ilmarinen Mutual Pension Insurance Co raised its position in Johnson & Johnson by 41.7% during the fourth quarter. Ilmarinen Mutual Pension Insurance Co now owns 356,600 shares of the company's stock worth $51,571,000 after acquiring an additional 105,000 shares during the last quarter. Nutshell Asset Management Ltd purchased a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $1,302,000. Russell Investments Group Ltd. grew its position in shares of Johnson & Johnson by 7.0% in the fourth quarter. Russell Investments Group Ltd. now owns 2,438,453 shares of the company's stock valued at $352,252,000 after purchasing an additional 158,873 shares during the last quarter. Finally, Rahlfs Capital LLC purchased a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $1,462,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Down 2.2 %

Shares of Johnson & Johnson stock traded down $3.27 during trading hours on Thursday, reaching $147.70. The stock had a trading volume of 7,100,109 shares, compared to its average volume of 7,913,908. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The firm has a market capitalization of $355.94 billion, a price-to-earnings ratio of 22.24, a P/E/G ratio of 2.56 and a beta of 0.49. The firm has a 50 day simple moving average of $159.50 and a two-hundred day simple moving average of $155.37.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts' consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm had revenue of $22.52 billion for the quarter, compared to analysts' expectations of $22.44 billion. During the same period in the previous year, the company posted $2.29 earnings per share. Johnson & Johnson's revenue was up 5.3% compared to the same quarter last year. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Citigroup lowered their target price on Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating on the stock in a report on Wednesday, December 11th. Guggenheim reiterated a "neutral" rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Stifel Nicolaus reduced their target price on shares of Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating on the stock in a report on Thursday, January 23rd. The Goldman Sachs Group upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and lifted their price target for the stock from $157.00 to $172.00 in a report on Wednesday. Finally, Raymond James reduced their price objective on shares of Johnson & Johnson from $170.00 to $165.00 and set an "outperform" rating on the stock in a research note on Thursday, January 23rd. Eight investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $171.67.

Insider Activity at Johnson & Johnson

In other news, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the sale, the executive vice president now owns 15,098 shares in the company, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the company's stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the transaction, the vice president now owns 21,001 shares of the company's stock, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is owned by insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.